Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 12;9:13184. doi: 10.1038/s41598-019-49711-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Human sample analysis using a molecular beacon NANP sensor. First, we want to confirm the applicability of ex vivo fluorescence in humans. (A) Profiling data for an AD-associated molecular beacon NANP sensor for normal and AD patients (ADAMBENA). Aβ_1–42 miR-106b, miR-153, miR-155, NFκB, NLRP3, Tau, STAT3, and Visfatin were used as markers in two plasma samples from each normal and AD patient. (B) The profiling data for an AD-associated molecular beacon NANP sensor for 4 AD patients (ADAMBENA). miR-106b, miR-155, miR-200a, miR-181a, miR-124b, miR-146b, miR-34a, and miR-153 were used as markers in miRNA, and Aβ_1–42 monomer, Aβ_1–42 oligomer, NLRP3, UCHL1, STAT3, Tau, Visfatin, IL-13, SORL1, Clusterin, ApoE4, ApoE3, and Nogo-A were used as markers in four plasma samples from the AD patients.